<DOC>
	<DOCNO>NCT02437422</DOCNO>
	<brief_summary>A Phase Ib , Open-Label , Single Arm Study Assess Safety , Pharmacokinetics , Impact Humoral Sensitization SANGUINATE Infusion Patients End Stage Renal Disease ( ESRD ) .</brief_summary>
	<brief_title>Study Assess Safety Impact Humoral Sensitization SANGUINATE Patients With End Stage Renal Disease</brief_title>
	<detailed_description>The purpose study investigate safety SANGUINATE humoral sensitization End Stage Renal Disease ( ESRD ) patient receive dialysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Patient diagnose End State Renal Disease require renal replacement therapy . 2 . Age 18 65 year age maintenance hemodialysis least 3 month prior study start ; 3 . Stable dialysis treatment regimen 3 time per week â‰¥ 2 month prior screen visit ; 4 . Hemoglobin &gt; 7.5 g/dL without clinical symptom ; 5 . Women childbearing potential must negative serum pregnancy test must use reliable method contraception study period ; 6 . Signed date informed write consent subject his/her legally authorize representative ; 1 . In judgment investigator patient good candidate study ; 2 . Blood transfusion last 90 day date Screening ; 3 . Symptoms electrocardiogram ( ECG ) base sign acute myocardial infarction , Unstable angina pectoris , decompensated heart failure , third degree heart block cardiac arrhythmia associate hemodynamic instability ; 4 . Total bilirubin great 1.5 mg/dL transaminase ( ALT , AST ) elevation great 2 time upper limit laboratory reference range evidence significant hepatic insufficiency ; 5 . Concurrent prior treatment within 90 day Screening investigational medication ; 6 . Chronic treatment ( determined Investigator ) immunosuppressive medication ( include corticosteroid ) within past 90 day Screening ; 7 . Evidence history regular alcohol abuse ; 8 . Screening laboratory result ( ) determine clinically significant investigator ; 9 . Screening laboratory result indicate HIVpositivity , previously diagnose AIDS , AIDS relate complex immunodeficiency ; 10 . Screening laboratory result laboratory result perform within one year indicate positivity hepatitis B surface antigen , hepatitis B core antibody , hepatitis C antibodies ; 11 . Uncontrolled Diabetes Mellitus ( Patients HbA1c &gt; 9 % screening )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>